• metastatic/advanced - colorectal cancer (mCRC) 2
• mCRC - (neo)adjuvant (NA)
• mCRC - 1st line (L1) 5
• mCRC - 2nd line (L2) 6
• endometrial cancer 10

 

• chemotherapy
• non platinum-based chemotherapy
• nucleoside analogues (pyrimidine/purine)
• capecitabine
• Standard of Care (SoC)
• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus bevacizumab
• atezolizumab plus cometinib
• atezolizumab plus FOLFOXIRI plus bevacizumab
• atezolizumab plus SoC
• avelumab based treatment
• avelumab alone
• durvalumab based treatment
• nivolumab based treatment
• nivolumab plus SoC
• pembrolizumab based treatment
• pembrolizumab alone
• Immune checkpoint association
• durvalumab plus tremelimumab
• nivolumab plus ipilimumab